Efficacy of Steroid Injection in Patients With Bifid Median Nerve Diagnosed Carpal Tunnel Syndrome

Launched by YUNUS BURAK BAYIR · Sep 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of steroid injections for treating Carpal Tunnel Syndrome (CTS) in patients who have a specific anatomical variation called a bifid median nerve. CTS occurs when the median nerve, which runs through the wrist, becomes compressed, causing pain, numbness, or weakness in the hand. The researchers want to find out if having a bifid median nerve affects how well steroid injections work compared to those who have a regular median nerve. This study is important because it could help improve treatment options for people with CTS.

To be eligible for this trial, participants need to be between 18 and 65 years old and have a confirmed diagnosis of mild to moderate Carpal Tunnel Syndrome. They must also show typical symptoms for at least three months and have a bifid median nerve identified through an ultrasound. Participants can expect to receive a steroid injection and be monitored for how well it relieves their symptoms. The trial aims to provide new insights into how different nerve structures can influence treatment success for Carpal Tunnel Syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Being between the ages of 18-65
• • Being clinically diagnosed with Carpal Tunnel Syndrome
• • Confirmation of mild and moderate Carpal Tunnel Syndrome diagnosis with EMG
• • Diagnosis of bifid median nerve after ultrasound evaluation, No variation was detected for the control group either.
• • Having typical Carpal Tunnel Syndrome symptoms for at least 3 months
• Exclusion Criteria:
• • History of polyneuropathy, brachial plexopathy, thoracic outlet syndrome, or wrist surgery
• • History of Inflammatory arthritis, hypothyroidism, pregnancy,rheumatological disorders or heart battery
• • current warfarin use, Prior steroid injection for CTS, trauma or neoplasm at the injection site, hypersensitivity to corticosteroids or skin infection at the injection site
• • other median nerve variations and presence of persistent median artery.